Evolus, Inc. (EOLS)Healthcare | Drug Manufacturers - Specialty & Generic | Newport Beach, United States | NasdaqGM
5.08 USD
-0.01
(-0.098%) ⇩
(April 21, 2026, 11:10 a.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:09 p.m. EDT
A critical divergence exists: while analyst models and forecasting statistics project a -14.8% downside over the next 45 days due to earnings deterioration and negative earnings, the speculator market is aggressively betting on a rally. The 'wall of calls' at $7.50–$10.00 suggests a belief in catalyst-driven upside (FDA approvals or partnerships) that the current price action hasn't yet validated. However, with insider tax sales and a negative P/E ratio, the fundamental risk remains high; the upside is purely sentiment-driven waiting for a fundamental event to trigger. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.077666 |
| AutoETS | 0.109744 |
| AutoARIMA | 0.109746 |
| MSTL | 0.117887 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.69 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.140 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 4.61 |
| Market Cap | 330,179,456 |
| Forward P/E | 21.32 |
| Beta | 1.00 |
| Profit Margins | -17.38% |
| Website | https://www.evolus.com |
As of April 18, 2026, 11:09 p.m. EDT: Options data reveals a distinct bullish skew with heavy Open Interest (OI) positioned in calls at strikes 7.5 and 10.0 for July and October expirations compared to negligible put placement across all timeframes. The ATM calls show a 'Top OI' spike at further OTM strikes, suggesting speculative positioning for a double-digit upside move to test resistance levels around $7.50-$10.00. In contrast, Put activity is minimal and concentrated only at-the-money, indicating a lack of bearish hedging. Implied volatility is elevated on calls (up to 1.16-1.53 for near-term), anticipating upside moves rather than downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.51434034 |
| Address1 | 520 Newport Center Drive |
| Address2 | Suite 1200 |
| All Time High | 39.5 |
| All Time Low | 2.85 |
| Ask | 6.37 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 703,260 |
| Average Daily Volume3 Month | 1,118,783 |
| Average Volume | 1,118,783 |
| Average Volume10Days | 703,260 |
| Beta | 0.998 |
| Bid | 3.66 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | -0.355 |
| City | Newport Beach |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.075 |
| Current Ratio | 1.898 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.11 |
| Day Low | 4.915 |
| Display Name | Evolus |
| Earnings Call Timestamp End | 1,777,926,600 |
| Earnings Call Timestamp Start | 1,777,926,600 |
| Earnings Timestamp | 1,777,924,800 |
| Earnings Timestamp End | 1,777,924,800 |
| Earnings Timestamp Start | 1,777,924,800 |
| Ebitda | -30,094,000 |
| Ebitda Margins | -0.10127 |
| Enterprise To Ebitda | -14.344 |
| Enterprise To Revenue | 1.453 |
| Enterprise Value | 431,674,752 |
| Eps Current Year | -0.122 |
| Eps Forward | 0.238 |
| Eps Trailing Twelve Months | -0.8 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5504 |
| Fifty Day Average Change | 0.5246 |
| Fifty Day Average Change Percent | 0.11528658 |
| Fifty Two Week Change Percent | -51.434032 |
| Fifty Two Week High | 12.28 |
| Fifty Two Week High Change | -7.205 |
| Fifty Two Week High Change Percent | -0.58672637 |
| Fifty Two Week Low | 3.86 |
| Fifty Two Week Low Change | 1.2149999 |
| Fifty Two Week Low Change Percent | 0.31476682 |
| Fifty Two Week Range | 3.86 - 12.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,518,100,200,000 |
| Float Shares | 49,240,003 |
| Forward Eps | 0.238 |
| Forward P E | 21.323528 |
| Free Cashflow | -26,697,750 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 334 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.66327006 |
| Gross Profits | 197,107,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16309 |
| Held Percent Institutions | 0.76515 |
| Implied Shares Outstanding | 65,059,990 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California. |
| Long Name | Evolus, Inc. |
| Market | us_market |
| Market Cap | 330,179,456 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_229087176 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -51,641,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 330,504,749 |
| Number Of Analyst Opinions | 6 |
| Open | 5.11 |
| Operating Cashflow | -42,265,000 |
| Operating Margins | -0.00322 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 949 284 4555 |
| Previous Close | 5.08 |
| Price Eps Current Year | -41.59836 |
| Price Hint | 2 |
| Price To Book | -14.295774 |
| Price To Sales Trailing12 Months | 1.1110569 |
| Profit Margins | -0.17377001 |
| Quick Ratio | 1.441 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -0.0050001144 |
| Regular Market Change Percent | -0.09842745 |
| Regular Market Day High | 5.11 |
| Regular Market Day Low | 4.915 |
| Regular Market Day Range | 4.915 - 5.11 |
| Regular Market Open | 5.11 |
| Regular Market Previous Close | 5.08 |
| Regular Market Price | 5.075 |
| Regular Market Time | 1,776,784,224 |
| Regular Market Volume | 209,764 |
| Return On Assets | -0.10252 |
| Revenue Growth | 0.144 |
| Revenue Per Share | 4.61 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 65,059,990 |
| Shares Percent Shares Out | 0.100200005 |
| Shares Short | 6,517,006 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,807,678 |
| Short Name | Evolus, Inc. Common Stock |
| Short Percent Of Float | 0.102299996 |
| Short Ratio | 3.99 |
| Source Interval | 15 |
| State | CA |
| Symbol | EOLS |
| Target High Price | 20.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 14.66667 |
| Target Median Price | 14.0 |
| Total Cash | 53,826,000 |
| Total Cash Per Share | 0.827 |
| Total Debt | 154,996,000 |
| Total Revenue | 297,176,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.333175 |
| Two Hundred Day Average Change | -1.2581754 |
| Two Hundred Day Average Change Percent | -0.19866423 |
| Type Disp | Equity |
| Volume | 209,764 |
| Website | https://www.evolus.com |
| Zip | 92,660 |